Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Females 18 years to 42 years of age who experienced gestational diabetes mellitus (GDM) during recent (within 12 months) pregnancy with prediabetic hyperglycemia determined by an oral glucose tolerance test (OGTT) with 75 g glucose postpartum. Study subjects will be inclusive of prior GDM women with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both (IFG/IGT) postpartum.~* Written consent for participation in the study~Exclusion Criteria:~* Cholestasis during the past pregnancy~* Any hepatic diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of unknown etiology)~* Serum aspartate transaminase (AST) and/or alanine aminotransferase (ALT) level exceeding more than twice normal lab values~* Presence of hypersensitivity to sitagliptin or other DPP-4 inhibitor~* Current use of metformin, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, or weight loss medications (prescription or over the counter \[OTC\])~* Prior use of medication to treat diabetes except gestational diabetes~* Use of drugs known to exacerbate glucose tolerance~* History of diabetes or prior use of medications to treat diabetes except GDM~* Creatinine clearance less than 60 ml/min~* Pregnancy planned during the coming two years~* Currently lactating~* Patient not willing to use adequate contraception during study period (unless sterilized)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin-Metformin (Type: EXPERIMENTAL): 50 mg/1000 mg twice a day (BID)
- Placebo pill (Type: PLACEBO_COMPARATOR): 1 pill/BID for 16 weeks
- Metformin (Type: ACTIVE_COMPARATOR): 1000 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).